Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics

Renovaro Inc. (NASDAQ:RENB) declared that the U.S. Patent and Trademark Office has granted its subsidiary BioSymetrics a Notice of Allowance for a new patent entitled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions.”

Renovaro obtains a U.S. patent for its AI-powered platform for medication discovery and diagnostics.

A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.

This extends Renovaro Inc. (NASDAQ:RENB)’s drug discovery and diagnostics platform by allowing for standardized integration of genomes, EHRs, imaging, and clinical trial data. For biomedical use applications, the technology facilitates distributed, real-time predictive analytics.

Renovaro Inc. (NASDAQ:RENB)’s groundbreaking U.S. Patent No. 11,379,757, which was awarded in July 2022 and covers ML pipeline optimization, is the basis for the new patent. CEO David Weinstein emphasized the strategic significance of this milestone in bolstering the firm’s scalable AI platform.

This advancement improves the company’s capacity to market AI solutions for clinical trials, rare diseases, and customized medicine while addressing significant data harmonization issues in pharmaceutical R&D. The patent backs the business’s larger expansion plan, collaborations, and life sciences licensing.

While we acknowledge the potential of RENB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RENB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.